Demographics and characteristics for all 1546 patients included in the pooled analysis
| Baseline characteristics . | All patients . | Rituximab . | P . | |
|---|---|---|---|---|
| No (N = 1004) . | Yes (N = 542) . | |||
| Age in years, median (range) | 40 (18-76) | 38 (18-73) | 42 (20-76) | <.001 |
| Gender, n (%) | ||||
| Male | 1228 (84) | 804 (87) | 424 (78) | .011 |
| Histology, n (%) | ||||
| BL/BLL | 399 (26) | 251 (25) | 148 (27) | |
| DLBCL | 1059 (69) | 680 (68) | 379 (70) | |
| Other | 88 (6) | 73 (7) | 15 (3) | |
| Age-adjusted IPI, n (%) | ||||
| 0 | 151 (12) | 104 (12) | 47 (11) | .85 |
| 1 | 384 (29) | 249 (29) | 135 (31) | |
| 2 | 519 (40) | 344 (40) | 175 (40) | |
| 3 | 250 (19) | 165 (19) | 85 (19) | |
| Treatment, n (%) | ||||
| Intensive regimen | 155 (10) | 77 (7) | 78 (14) | <.001 |
| CHOP | 632 (41) | 391 (39) | 241 (44) | |
| Low-dose CHOP | 165 (11) | 165 (16) | 0 | |
| EPOCH | 166 (11) | 17 (2) | 149 (27) | |
| VS | 41 (3) | 41 (4) | 0 | |
| ACVBP/LNHIV91 | 158 (10) | 158 (16) | 0 | |
| CDE | 191 (12) | 117 (12) | 74 (14) | |
| Remick regimen | 38 (2) | 38 (4) | 0 | |
| GCSF, n (%) | 1467 (99) | 986 (98) | 481 (100) | <.001 |
| Concurrent cART, n (%) | 779 (52) | 423 (43) | 356 (69) | <.001 |
| CD4 count, cells/μL (median; IQR) | 248 (101-652) | 334 (120-1200) | 179 (74-330) | <.001 |
| Viral load, copies/μL (median; IQR) | 23 801 (600-160 000) | 42 000 (930-190 461) | 17 420 (442-145 000) | .084 |
| History of prior AIDS | 480 (38) | 302 (37) | 178 (39) | .429 |
| CD4 <50 cells/µL, n (%) | 207 (14) | 120 (13) | 87 (17) | .025 |
| Enrollment date (year) | ||||
| 89-95 | 388 (25) | 388 (39) | 0 | <.001 |
| 96-97 | 298 (19) | 298 (30) | 0 | |
| 98-00 | 396 (26) | 256 (26) | 140 (26) | |
| 01-04 | 282 (18) | 49 (5) | 233 (43) | |
| 05-10 | 182 (12) | 13 (1) | 169 (31) | |
| Median follow-up, years (IQR) | 1.2 (0.4-4.4) | 0.9 (0.4-4.0) | 2.3 (0.6-4.6) | <.001 |
| CR, n (%) | 791 (57) | 427 (49) | 364 (71) | <.001 |
| Progression, n (%) | 625 (40) | 460 (46) | 165 (30) | <.001 |
| Survival,* n (%) | 650 (43) | 303 (32) | 347 (64) | <.001 |
| Baseline characteristics . | All patients . | Rituximab . | P . | |
|---|---|---|---|---|
| No (N = 1004) . | Yes (N = 542) . | |||
| Age in years, median (range) | 40 (18-76) | 38 (18-73) | 42 (20-76) | <.001 |
| Gender, n (%) | ||||
| Male | 1228 (84) | 804 (87) | 424 (78) | .011 |
| Histology, n (%) | ||||
| BL/BLL | 399 (26) | 251 (25) | 148 (27) | |
| DLBCL | 1059 (69) | 680 (68) | 379 (70) | |
| Other | 88 (6) | 73 (7) | 15 (3) | |
| Age-adjusted IPI, n (%) | ||||
| 0 | 151 (12) | 104 (12) | 47 (11) | .85 |
| 1 | 384 (29) | 249 (29) | 135 (31) | |
| 2 | 519 (40) | 344 (40) | 175 (40) | |
| 3 | 250 (19) | 165 (19) | 85 (19) | |
| Treatment, n (%) | ||||
| Intensive regimen | 155 (10) | 77 (7) | 78 (14) | <.001 |
| CHOP | 632 (41) | 391 (39) | 241 (44) | |
| Low-dose CHOP | 165 (11) | 165 (16) | 0 | |
| EPOCH | 166 (11) | 17 (2) | 149 (27) | |
| VS | 41 (3) | 41 (4) | 0 | |
| ACVBP/LNHIV91 | 158 (10) | 158 (16) | 0 | |
| CDE | 191 (12) | 117 (12) | 74 (14) | |
| Remick regimen | 38 (2) | 38 (4) | 0 | |
| GCSF, n (%) | 1467 (99) | 986 (98) | 481 (100) | <.001 |
| Concurrent cART, n (%) | 779 (52) | 423 (43) | 356 (69) | <.001 |
| CD4 count, cells/μL (median; IQR) | 248 (101-652) | 334 (120-1200) | 179 (74-330) | <.001 |
| Viral load, copies/μL (median; IQR) | 23 801 (600-160 000) | 42 000 (930-190 461) | 17 420 (442-145 000) | .084 |
| History of prior AIDS | 480 (38) | 302 (37) | 178 (39) | .429 |
| CD4 <50 cells/µL, n (%) | 207 (14) | 120 (13) | 87 (17) | .025 |
| Enrollment date (year) | ||||
| 89-95 | 388 (25) | 388 (39) | 0 | <.001 |
| 96-97 | 298 (19) | 298 (30) | 0 | |
| 98-00 | 396 (26) | 256 (26) | 140 (26) | |
| 01-04 | 282 (18) | 49 (5) | 233 (43) | |
| 05-10 | 182 (12) | 13 (1) | 169 (31) | |
| Median follow-up, years (IQR) | 1.2 (0.4-4.4) | 0.9 (0.4-4.0) | 2.3 (0.6-4.6) | <.001 |
| CR, n (%) | 791 (57) | 427 (49) | 364 (71) | <.001 |
| Progression, n (%) | 625 (40) | 460 (46) | 165 (30) | <.001 |
| Survival,* n (%) | 650 (43) | 303 (32) | 347 (64) | <.001 |
Patients alive at the end of follow-up.